

Linking Ayurveda and Western medicine by integrative analysis

Fazlin Mohd Fauzi^{1,2}, Alexios Koutsoukas¹, Robert Lowe³, Kalpana Joshi⁴, Tai-Ping Fan⁵, Robert C. Glen¹, Andreas Bender¹

¹Unilever Centre for Molecular Science Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, CB2 1EW, United Kingdom, ²Universiti Teknologi MARA (UiTM) Malaysia, 40 450 Shah Alam, Selangor, Malaysia, ³Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London E1 2AT, United Kingdom, ⁴School of Health Sciences, University of Pune, India, ⁵Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, United Kingdom

ABSTRACT

In this article, we discuss our recent work in elucidating the mode-of-action of compounds used in traditional medicine including Ayurvedic medicine. Using computational ('in silico') approach, we predict potential targets for Ayurvedic anti-cancer compounds, obtained from the Indian Plant Anticancer Database given its chemical structure. In our analysis, we observed that: (i) the targets predicted can be connected to cancer pathogenesis i.e. steroid-5-alpha reductase 1 and 2 and estrogen receptor- β , and (ii) predominantly hormone-dependent cancer targets were predicted for the anti-cancer compounds. Through the use of our in silico target prediction, we conclude that understanding how traditional medicine such as Ayurveda work through linking with the 'western' understanding of chemistry and protein targets can be a fruitful avenue in addition to bridging the gap between the two different schools of thinking. Given that compounds used in Ayurveda have been tested and used for thousands of years (although not in the same approach as Western medicine), they can potentially be developed into potential new drugs. Hence, to further advance the case of Ayurvedic medicine, we put forward some suggestions namely: (a) employing and integrating novel analytical methods given the advancements of 'omics' and (b) sharing experimental data and clinical results on studies done on Ayurvedic compounds in an easy and accessible way.

Key words: *Ayurveda, in silico target prediction, mode-of-action, anti-cancer compounds*

For thousands of years, ingredients from Ayurvedic medicine (though often not in controlled clinical settings) have been connected to efficacy in man^[1]-point in case, the introduction of the antihypertensive drug reserpine derived from *Rauwolfia serpentina* Benth.^[2] Additionally, natural products present in Ayurvedic formulations form an interesting source of new molecular entities. This is particularly compelling since from 1981 to 2007, 67% of the new medicines introduced in the "western" world could

be traced back to natural products themselves, or they were natural product-inspired.^[3] Furthermore, Ayurveda relies on the synergies of the different ingredients in a formulation, to not only cure the disease in question but also reduce side effects and improve adaptive resistance.^[1,4] This approach is now also more and more considered in other cultures, such as by considering combination treatments of drugs.^[5] To illustrate the effectiveness of the synergistic approach applied in Ayurveda, we highlight a case study published by Prakash *et al.*,^[6] in this very journal, where a 47-year-old patient was treated successfully with a formulation consisting of navajeevan, keharubapisti, and kamadudha rasa for acute promyelocytic leukemia after undergoing two cycles of chemotherapy (treated with cytarabine and daunorubicin the first time, then treated with etoposide and idarubicin) and relapsing both times. From the year 1998 to 2003, the patient received the Ayurvedic treatment for 3 months every year and exhibited no signs of renal and liver toxicity and at the time of publication.^[6] The patient was cancer-free for 13 years from the start of the Ayurvedic therapy.^[6]

Despite these advantages, however, there are still major challenges that prevent the even more widespread

Address for correspondence:

Dr. Andreas Bender, Unilever Centre for Molecular Science Informatics, University of Cambridge Lensfield Road, CB2 1EW Cambridge, United Kingdom
Email : ab454@cam.ac.uk

Received: 14-Apr-2013

Accepted: 29-Apr-2013

Revised: 10-May-2013

Access this article online

Quick Response Code:



Website:



www.jaim.in

DOI:

10.4103/0975-9476.113882

Table 1: The target (s) predicted for two active ingredients of Ayurvedic medicines used against cancer, as annotated in the Indian Plant Anticancer Compounds Database.^[10]

Given our aim to relate both traditional and “western” thinking, we used databases from both domains to rationalize the mode-of-action of Ayurvedic medicine. Listed are both target hypothesis generated *via* computational methods, but also a direct target annotation found in the ChEMBL database^[23] (shown in bold). It can be seen that the targets predicted for the two compounds are consistent with the information in the literature to be involved in cancer pathogenesis, and hence, we anticipate that linking ayurvedic and “western” understanding of disease and treatments is a very fruitful option to pursue in the future

| Structure | Predicted target (s)/ annotated target in ChEMBL | Literature support |
|--|--|--|
| <p>CHEMBL273862</p>  | <p>DNA topoisomerase 1 ER-β</p> | <p>DNA topoisomerase facilitates the separation of the DNA strand for the purpose of replication and transcription.^[45] camptothecin, an anticancer drug discovered from the Chinese tree, <i>Camptotheca acuminata</i> blocks this enzyme.^[46] ER-β was found to be expressed in breast cancer with ER-α and PR^[47]</p> |
| <p>CHEMBL463810</p>  | <p>Steroid 5-α-reductase 1 Steroid 5-α-reductase 2</p> | <p>Both enzymes have been found to be involved in the progression of prostate cancer.^[48] The concentration of steroid 5-α-reductase 1 have been found to be higher in malignant prostate cancer, whereas steroid 5-α-reductase 2 was more pronounced in the benign state^[48]</p> |

ER- β =Estrogen receptor- β , PR=Progesterone receptor

acceptance of Ayurvedic approaches. Four of these challenges were recently outlined by Corson and Crews:^[7] (i) the isolation of active constituents; (ii) the synthesis of active constituents; (iii) the elucidation of the mechanism of action (MOA); and (iv) the development as a drug. In particular, the elucidation or explanation of the MOA^[7] is of relevance to our current work that has recently been published^[8] and which we would like to alert you to with this article, in order to offer one possibility of bridging disease and treatment perceptions of both traditional and “western” schools of thinking. Given the renewed interest ‘in the west’ into traditional approaches to healing, our work has also found considerable resonance in western news media, such as with the BBC.^[9]

In our study,^[8] we employed the use of computational (“*in silico*”) methods to predict protein targets modulated by compounds used in Ayurveda, as well as traditional Chinese medicine, and subsequently aimed to understand the MOA predictions of active ingredients in the context of their therapeutic uses. While further details and successful examples are given in the publication, we will only illustrate our abilities to rationalize MOAs for Ayurvedic medicines here, analyzing a set of active ingredients from the Indian Plant Anticancer Compounds Database as shown in Table 1.^[10] (Interestingly, both in the “west” and

in the realm of traditional medicines electronic databases have recently developed greatly; the equivalent database in the context of “western” drug discovery is the ChEMBL database^[11] which we also employed in the study described here.) The first compound, labeled as CHEMBL273862 (10-hydroxycamptothecin), is a derivative of the anticancer compound camptothecin of the *Camptotheca acuminata* plant^[12] and the second compound, labeled as CHEMBL463810 (Cholesta-4,25-diene-3,6,24-trione) originated from the red alga *galaxaura marginata*.^[13]

As outlined in Table 1, we can show that the targets modulated by Ayurvedic medicines used for cancer treatment can be connected to cancer pathogenesis, as understood using “western” approaches. In this particular case, predominantly hormone-dependent cancer targets such as steroid-5- α -reductase 1 and 2, and the estrogen receptor- β were predicted as targets for the anticancer compounds shown structurally, which are used as active ingredients in Ayurveda. (More information, such as the top 10 enriched targets predicted for 560 ayurvedic anticancer compounds which also list additional hormone-dependent cancer targets, can be seen in the original publication.^[8])

Given the above-and outlined in more detail in the original publication-we conclude that bridging treatment

approaches from traditional medicines, such as Ayurveda, with “western” understanding of chemistry, targets and pathways, is a very fruitful avenue to understand in more detail how traditional medicines work. Admittedly, this will be difficult to achieve in many cases, since active ingredients are often not known, and the same can be said for bioactivities of chemical structures as well as our scarce knowledge of the impact of modulating protein targets on disease states. Still, given that Ayurveda starts with the ability to modulate a disease-relevant phenotype (which has been frequently a reason for concern in “western” medicine^[14]) combined with our growing knowledge in databases of the above types, we anticipate that methods such as the one presented here will increase in importance in the future. We hope that this development will be mutually beneficial; to learn on the one hand more about the inner workings of traditional medicines, and on the other hand to eventually also increase recognition of traditional ways of treating disease in the “western” world.

Finally, we would like to leave the readers with a few suggestions to advance the case of Ayurvedic medicine, particularly but not only in the “western” world:

1. Utilizing and integrating novel analytical methods, in particular given the advancements of “omic” technologies, that enable the simultaneous study of multiple molecular effects of Ayurvedic treatments using, for example, metabolomics, genomic, as well as proteomic analysis, and
2. Sharing information about experimental data and clinical results from Ayurvedic studies with the public in an easily accessible way. In the opinion of the authors, many of the assumptions being made about Ayurvedic medicine “in the west” are simply based on lack of reliable and accessible information.

ACKNOWLEDGMENT

The authors thank Universiti Teknologi MARA, Malaysia, Ministry of Higher Education of Malaysia and Unilever for funding.

REFERENCES

1. Patwardhan B, Mashelkar RA. Traditional medicine-inspired approached to drug discovery: Can Ayurveda show the way forward. *Drug Discov Today* 2009;14:804-11.
2. Vakil R.J. A clinical trial of *Rauwolfia serpentina* in essential

- hypertension. *Br Heart J* 1949;11:350-5.
3. Schmidt BM, Ribnicky DM, Lipsky PE, Raskin I. Revisiting the ancient concept of botanical therapeutics. *Nat Chem Biol* 2007;3:360-6.
4. Xutian S, Zhang J, Louise W. New exploration and understanding of traditional Chinese medicine. *Am J Chin Med* 2009;37:411-26.
5. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: When the whole is greater than the sum of the parts. *Drug Discov Today* 2007;12:34-42.
6. Prakash B, Parikh PM, Pal SK. Herbo-mineral ayurvedic treatment in a high risk acute promyelocytic leukemia patient with second relapse: 12 years follow up. *J Ayurveda Integr Med* 2010;1:215-8.
7. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: Triumphs and trials. *Cell* 2007;130:769-74.
8. Mohd Fauzi F, Koutsoukas A, Lowe R, Joshi K, Fan TP, Glen RC, *et al.* Chemogenomics approached to rationalizing the mode-of-action of traditional Chinese and Ayurvedic medicine. *J Chem Inf Model* 2013;53:661-73.
9. Available from: http://www.bbc.co.uk/mundo/noticias/2013/03/130318_salud_medicina_asia_acupuntura_gtg.shtml [Last accessed on 2013 Apr 05].
10. Vetrivel U, Subramanian N, Pilla K, Campus R. Bioinformatics InPACdb-Indian plant anticancer compounds database Bioinformatics. *Cancer* 2009;2063:71-4.
11. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, *et al.* ChEMBL: A large-scale bioactivity database for drug discovery. *Nucleic Acids Res* 2012;40:D1100-7.
12. Wu WB, Ou JB, Huang ZH, Chen SB, Ou TM, Tan JH, *et al.* Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors. *Eur J Med Chem* 2011;46:3339-47.
13. Sheu JH, Huang SY, Wang GH, Duh CY. Study on cytotoxic oxygenated desmosterols isolated from the red alga *Galaxaura marginata*. *J Nat Prod* 1997;60:900-3.
14. Arrowsmith J. Trial watch: Phase III and submission failures: 2007-2010. *Nat Rev Drug Discov* 2011;10:87.
15. Pommier Y, Leo E, Zhang H, Marchand C. DNA Topoisomerases and their poisoning by anticancer and antibacterial drugs. *Chem Biol* 2010;17:421-33.
16. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant Antitumor Agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata* 1,2. *J Am Chem Soc* 1966;88:3888-90.
17. Jarvinen TA, Pelto-Huikko M, Holli K, Isola J. Estrogen receptor b is coexpressed with ERa and PR and associated with nodal status, grade and proliferation rate in breast cancer. *Am J Pathol* 2000;156:29-35.
18. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and Type 25α-reductase expression in the development and progression of prostate cancer. *Eur Urol* 2008;53:244-52.

How to cite this article: Fauzi FM, Koutsoukas A, Lowe R, Joshi K, Fan T, Glen RC, *et al.* Linking Ayurveda and Western medicine by integrative analysis. *J Ayurveda Integr Med* 2013;4:117-9.

Source of Support: Nil, **Conflict of Interest:** None declared.